Literature DB >> 19664826

Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.

Dawn I Velligan1, Larry Alphs, Scott Lancaster, Robert Morlock, Jim Mintz.   

Abstract

We examined whether changes in negative symptoms, as measured by scores on the 16-item Negative Symptom Assessment scale (NSA-16), were associated with changes in functional outcome. A group of 125 stable outpatients with schizophrenia were assessed at baseline and at 6 months using the NSA-16, the Brief Psychiatric Rating Scale, and multiple measures of functional outcome. Baseline adjusted regression coefficients indicated moderate correlations between negative symptoms and functional outcomes when baseline values of both variables were controlled. Results were nearly identical when we controlled for positive symptoms. Cross-lag panel correlations and Structural Equation Modeling were used to examine whether changes in negative symptoms drove changes in functional outcomes over time. Results indicated that negative symptoms drove the changes in the Social and Occupational Functioning Scale (SOFAS) rather than the reverse. Measures of Quality of Life and measures of negative symptoms may be assessing overlapping constructs or changes in both may be driven by a third variable. Negative symptoms were unrelated over time to scores on a performance-based measure of functional capacity. This study indicates that the relationship between negative symptom change and the change in functional outcomes is complex, and points to potential issues in selection of assessments.

Entities:  

Mesh:

Year:  2009        PMID: 19664826     DOI: 10.1016/j.psychres.2008.10.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  19 in total

1.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

2.  Methodological issues in negative symptom trials.

Authors:  Stephen R Marder; David G Daniel; Larry Alphs; A George Awad; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2011-01-26       Impact factor: 9.306

Review 3.  Pharmacological treatment of negative symptoms in schizophrenia.

Authors:  Hans-Jürgen Möller; Pal Czobor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-21       Impact factor: 5.270

4.  Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial.

Authors:  Samantha V Abram; Lize De Coster; Brian J Roach; Bryon A Mueller; Theo G M van Erp; Vince D Calhoun; Adrian Preda; Kelvin O Lim; Jessica A Turner; Judith M Ford; Daniel H Mathalon; Joshua D Woolley
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

5.  Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?

Authors:  Sofia Brissos; Vicent Balanzá-Martinez; Vasco Videira Dias; Ana Isabel Carita; Maria Luisa Figueira
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-08       Impact factor: 5.270

6.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

7.  The importance of measuring psychosocial functioning in schizophrenia.

Authors:  Sofia Brissos; Andrew Molodynski; Vasco Videira Dias; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2011-06-24       Impact factor: 3.455

Review 8.  Mirtazapine adjunct for people with schizophrenia.

Authors:  Luke A Perry; Dhruvesh Ramson; Suzanne Stricklin
Journal:  Cochrane Database Syst Rev       Date:  2018-05-26

9.  Validation of the German Version of the Social Functioning Scale (SFS) for schizophrenia.

Authors:  Jona R Iffland; Denise Lockhofen; Harald Gruppe; Bernd Gallhofer; Gebhard Sammer; Bernd Hanewald
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

10.  The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Authors:  Lei Chen; Joseph A Johnston; Bruce J Kinon; Virginia Stauffer; Paul Succop; Tiago R Marques; Haya Ascher-Svanum
Journal:  BMC Psychiatry       Date:  2013-11-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.